Clariane stock among the sharpest declines on the SBF 120, −13% in one month
The share of the nursing home and home care services group is posting a severe decline in this first October trading session, in a Paris market itself oriented downward. The fall occurs as the yield on French ten-year debt is flirting with its highest levels in more than a decade, against a backdrop of strong budget uncertainty.
A sharp drop that brings monthly losses to more than 13% of capital
Clariane is down 7.69% to €3.46 during trading, ranking among the sharpest declines on the SBF 120, while the index itself falls 1.16%. The day's decline amplifies an already well-established trend: the share has dropped 13.2% over one month and 15.86% over the quarter. The slide places the price well below the three reference moving averages, with gaps exceeding 12% below the MA20 (€3.93), the MA50 (€3.98) and the MA200 (€3.94).
The 2% rebound recorded on Tuesday, September 29 has therefore not held: the share has fallen back below all of these benchmarks in a single session. Emeis, the only comparable value available, is also declining 5.82% during the session, a sign of broader sector pressure on care and accommodation operators across Europe.
RSI at 38 reflects persistent selling pressure, without clear oversold conditions
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The RSI at 38 remains in weak territory without signaling an extreme oversold configuration, which leaves room for further decline before reaching more pronounced levels of selling exhaustion. The price (€3.46) is well below the former support at €3.75, now transformed into resistance, and the upper resistance at €4.06 is moving further away. In the background, the rise in French yields (the French ten-year reaches 4.86% in trading, close to its 4.87% peak recorded in 2008) increases the financing costs for debt-intensive operators, a variable that ranks among the risks identified during the publication of H1 2026 results on July 29, 2026.
On that occasion, the group had also highlighted the objective of improving its EBITDA margin by 100 to 150 basis points by the end of 2026, as well as the refinancing of €1,063 million completed in the second half. Despite these financial consolidation operations, the market is punishing the share vigorously, bringing the price to its lowest level in several weeks. The €3.75 threshold remains the first level to reclaim in order to stabilize the trend.
SectorServices et infrastructure de santé›Etablissements de santé / EHPAD
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 2 699 millions d'euros
Quarterly revenue: 2 699 millions d'euros
Revenue growth: 1,6 %
EBITDA: 524 millions d'euros
EBITDA margin: 10,4 %
Net income: -47,5 millions d'euros
Free cash flow: 20 millions d'euros
3 020 millions d'euros
Guidance from the release
Le Groupe s'appuiera principalement sur la poursuite de l'amélioration de la performance opérationnelle et le maintien d'une stricte discipline d'investissements
Risks mentioned
Environnement géopolitique complexe affectant les opérations de refinancement
Exposition aux épisodes climatiques frappant durement certains territoires en Europe
Pression inflationniste continue sur les coûts opérationnels malgré les gains tarifaires
Opportunities identified
Amélioration de la marge EBITDA de 100-150 points de base d'ici fin 2026
Croissance des volumes d'activité portée par l'augmentation progressive des taux d'occupation
Refinancement réussi de €1 063m renforçant la flexibilité financière et réduisant le coût de la dette
Outlook / guidance
Expected revenue: 5 522 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.